IP Library › Granted Patent US 9,890,127
Granted Patent B2
US 9,890,127 · App. 14/775,354 · Granted Feb 13, 2018

Compounds and compositions for the treatment of cancer

Inventors: Timothy A. Lewis (Marlborough, MA); Benito Munoz (Newtonville, MA); Lucian De Waal (Watertown, MA); Heidi Greulich (Arlington, MA); Matthew Meyerson (Concord, MA); Lara Nicole Gechijian (Lincoln, MA)
Assignees: The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
C07D237/04C07D401/10C07D403/10C07D413/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,890,127
App. No.
14/775,354
Granted
Feb 13, 2018
Kind
B2
Abstract

Disclosed are compounds, such as pyridazinones, that can be, inter alia, used for treating cancer.

Claims (18)

1. A compound having a formula of:

or a pharmaceutically acceptable salt or ester thereof.

2. A pharmaceutical composition comprising a compound having a formula of:

or a pharmaceutically acceptable salt or ester thereof.

3. The compound of claim 1 having a formula of:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 having a formula of:

or an ester thereof.

5. The pharmaceutical composition of claim 2 , wherein the compound has a formula of:

or a pharmaceutically acceptable salt thereof.

6. The pharmaceutical composition of claim 2 , wherein the compound has a formula of:

or an ester thereof.

7. The pharmaceutical composition of claim 2 , wherein the compound, or a pharmaceutically acceptable salt thereof, is present in amount of at least 90% optical purity.

8. The pharmaceutical composition of claim 2 , wherein the compound, or a pharmaceutically acceptable salt or ester thereof, is present in amount of at least 95% optical purity.

9. The pharmaceutical composition of claim 2 , wherein the compound, or a pharmaceutically acceptable salt or ester thereof, is present in amount of at least 96% optical purity.

10. The pharmaceutical composition of claim 2 , wherein the compound, or a pharmaceutically acceptable salt or ester thereof, is present in amount of at least 98% optical purity.

11. The pharmaceutical composition of claim 2 , wherein the compound, or a pharmaceutically acceptable salt or ester thereof, is present in amount of at least 99% optical purity.

12. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is suitable for oral or parenteral administration.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: LEWIS, TIMOTHY; MUNOZ, BENITO; GRECHIJIAN, LARA NICOLE
To: THE BROAD INSTITUTE, INC.
Reel/Frame 043729/0267 →
CONFIRMATORY LICENSE Recorded Dec 7, 2015
From: BROAD INSTITUTE, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037222/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2015
From: DE WAAL, LUCIAN; GREULICH, HEIDI; MEYERSON, MATTHEW
To: DANA FARBER CANCER INSTITUTE, INC.
Reel/Frame 036917/0839 →
Continuity (2)
Provisional Application 61776520 · Mar 11, 2013
Related Publication 20160016913A1 · Jan 21, 2016